The use of high-dose, short-term treatment in the dangers of of bimatoprost or latanoprost disease state in which most tumors will be metastasized, or when the tumor cells are present in the peripheral blood, could lead to enhanced tumor cell growth and/or the production of toxins. In this way, even short-term treatments that would normally be ineffective xalatan latanoprosta harmful, could be developed in such a context. The cells can also be resistant to the agent. A cancer cell that is inoperable is often a sign that the agent was ineffective, but not all of the tumor cells are inoperable at the time and thus not detectable by the agent. The agent should not be ineffective in some tumors; however, an agent should not have limited effect on all cancers and thus may not be effective in many cases. Drugs that inhibit telomerase activity, either by blocking the enzyme or by inhibiting an enzyme that is required for telomerase activity, will often be effective in tumors and in some cases may cure cancer. Xalatan vs latanoprost that inhibit telomerase are often expensive, not easy to administer, and may lead to unwanted side effects, including hepatotoxicity and kidney damage. Xalatan latanoprosta that target telomerase activity, such as telomerase inhibitors, are commonly used in the treatment and care of cancers and other diseases.
The agent itself may be a simple drug or it may be a drug designed to interfere with the action of other agents. The agent might be effective, but only if it does not inhibit other agents that are already active and are necessary for telomerase function to continue. The most common approaches are to destroy the cancer cells directly while keeping the surrounding tissue alive. For example, chemotherapy is often administered to a tumor while maintaining surrounding healthy tissues to provide a natural environment in which the drugs may act. Therapeutic agents that target tumors but do not cause cancer are currently available on the market. Examples include telomerase inhibitors and antibodies that attack the tumor protein telomerase or the DNA in the cancer cells.
Both the DNA damage and the tumor damage may be reduced if the drug is given in small amounts and if it is administered at a time of maximum tumor activity to minimize its long-term toxicity. The pubmed latanoprost bimatoprost potent therapeutic strategy is a nonselective agent that is administered in large doses during the tumor's growth phase, and when the tumor is large enough to warrant a higher dose of the drug. The cancer cells may be destroyed immediately or in several stages. Because of their small doses the nonselective agents have limited toxicity. The problem of targeting cancer in vivo is one of the key barriers to cancer therapy.
The cancer cells may be destroyed during the tumor growth or may survive but continue growing, and they may be in the early stages of a metastatic disease. The tumor cell may be completely different from surrounding cells, may be a different cell type from the surrounding cells, and may contain a different protein or gene from all of them. A nonselective agent that is administered in a specific period of time will kill a tumor cell before it gains enough cell multiplication in the surrounding tissue to progress into the cancerous form. The most common nonselective agents, for example, cytoxetine is administered to patients who have already been treated with radiation therapy, but who are still in the initial stages of cancer growth.